Unknown

Dataset Information

0

BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights.


ABSTRACT: Colorectal cancer (CRC) is one of the leading causes of mortality and morbidity in the world. It is a heterogeneous disease, which can be classified into different subtypes, characterized by specific molecular and morphological alterations. In this context, BRAF mutations are found in about 10% of CRC patients and define a particular subtype, characterized by a dismal prognosis, with a median survival of less than 12 months. Chemotherapy plus bevacizumab is the current standard therapy in first-line treatment of BRAF-mutated metastatic CRC (mCRC), with triplet (FOLFOXIRI) plus bevacizumab as a valid option in patients with a good performance status. BRAF inhibitors are not so effective as compared to melanoma, because of various resistance mechanisms. However, the recently published results of the BEACON trial will establish a new standard of care in this setting. This review provides insights into the molecular underpinnings underlying the resistance to standard treatment of BRAF-mutated CRCs, with a focus on their molecular heterogeneity and on the research perspectives both from a translational and a clinical point of view.

SUBMITTER: Caputo F 

PROVIDER: S-EPMC6861966 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights.

Caputo Francesco F   Santini Chiara C   Bardasi Camilla C   Cerma Krisida K   Casadei-Gardini Andrea A   Spallanzani Andrea A   Andrikou Kalliopi K   Cascinu Stefano S   Gelsomino Fabio F  

International journal of molecular sciences 20191028 21


Colorectal cancer (CRC) is one of the leading causes of mortality and morbidity in the world. It is a heterogeneous disease, which can be classified into different subtypes, characterized by specific molecular and morphological alterations. In this context, BRAF mutations are found in about 10% of CRC patients and define a particular subtype, characterized by a dismal prognosis, with a median survival of less than 12 months. Chemotherapy plus bevacizumab is the current standard therapy in first-  ...[more]

Similar Datasets

| S-EPMC6990491 | biostudies-literature
| S-EPMC7260582 | biostudies-literature
| S-EPMC6889398 | biostudies-literature
| S-EPMC4839821 | biostudies-other
| S-EPMC8409311 | biostudies-literature
| S-EPMC7720726 | biostudies-literature
| S-EPMC8253290 | biostudies-literature
| S-EPMC5143296 | biostudies-literature
| S-EPMC6292791 | biostudies-literature
| S-EPMC4669589 | biostudies-literature